89bio Inc. (ETNB)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Well, welcome, everyone, and it's really a privilege for me to introduce our next participating company at the Cantor Global Healthcare Conference. First time Steve Seedhouse from the biotech team.
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director So welcome to the next session of the Citi Biopharma back-to-school event. So my name is Geoff Meacham.
89bio: Promising As Pegozafermin Nears Phase 3 Readout
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.
89bio Inc. Profile
| - Industry | - Sector | Rohan Palekar CEO | NASDAQ (NMS) Exchange | 282559103 CUSIP |
| US Country | 93 Employees | - Last Dividend | - Last Split | 11 Nov 2019 IPO Date |
Overview
89bio, Inc. is a clinical-stage biopharmaceutical company that is at the forefront of developing innovative therapies designed to combat liver and cardio-metabolic diseases. The company, which was founded in 2018, reflects a modern approach to addressing these serious health issues, leveraging cutting-edge science and medical research. Based in San Francisco, California, 89bio is dedicated to transforming the treatment landscape for patients suffering from these conditions, with a focus on nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia, among others.
Products and Services
- Pegozafermin
Pegozafermin stands out as 89bio's leading product candidate, embodying the company's commitment to innovation in treating liver and cardio-metabolic diseases. It is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), which offers a novel approach to managing conditions characterized by metabolic dysfunction. Pegozafermin is currently under clinical development for two primary applications:
- Treatment of Nonalcoholic Steatohepatitis (NASH): A serious liver disease characterized by fat accumulation, inflammation, and damage, NASH is a leading cause of cirrhosis and liver failure. Pegozafermin aims to address the underlying metabolic disturbances contributing to NASH, offering hope for patients with this condition.
- Treatment of Severe Hypertriglyceridemia: This condition is marked by extremely high levels of triglycerides in the blood, increasing the risk of cardiovascular disease. By leveraging the metabolic-regulating properties of FGF21, pegozafermin offers a promising approach to reducing triglyceride levels and thereby mitigating the risk of associated heart conditions.
Contact Information
